Lei Ding1, Liping Wang1, Jian Yin1, Zhiyi Fan1, Zijing He1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Anesthesiology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract
OBJECTIVE: To evaluate changes in chest X-rays, pulmonary function tests (PFTs) and quality of life in female breast cancer patients who had been treated with four cycles of neoadjuvant chemotherapy consisting of a regimen of cyclophosphamide, epirubicin and 5-fluorouracil (CEF regimen), and to determine the correlation between pulmonary function parameters and declined quality of life. METHODS: Twenty-nine eligible female patients diagnosed with breast cancer at the first visit who were 20-60 years old, were classified as the American Society of Anesthesiologists (ASA) I-II and patients whose body mass index (BMI) <30 kg/m2 were recruited and subjected to chest X-ray examinations, PFTs and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire before and after receiving 4 cycles of the CEF regimen. RESULTS: In this study, chest X-rays showed no abnormal changes after chemotherapy, but significant decreases in carbon monoxide diffusing capacity (DLCO) and percentage of the DLCO predicted value (DLCO%) (P<0.001). A significant increase in maximal ventilatory volume (MVV) (P=0.004) was observed, and most patients experienced dyspnea (P=0.031) and fatigue (P<0.001). However, there was no significant correlation between the changes in these PFTs parameters and the results of the EORTC QLQ-C30 (P>0.05). CONCLUSIONS: Neoadjuvant chemotherapy can reduce lung diffusion function and quality of life in females with breast cancer.
OBJECTIVE: To evaluate changes in chest X-rays, pulmonary function tests (PFTs) and quality of life in female breast cancer patients who had been treated with four cycles of neoadjuvant chemotherapy consisting of a regimen of cyclophosphamide, epirubicin and 5-fluorouracil (CEF regimen), and to determine the correlation between pulmonary function parameters and declined quality of life. METHODS: Twenty-nine eligible female patients diagnosed with breast cancer at the first visit who were 20-60 years old, were classified as the American Society of Anesthesiologists (ASA) I-II and patients whose body mass index (BMI) <30 kg/m2 were recruited and subjected to chest X-ray examinations, PFTs and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire before and after receiving 4 cycles of the CEF regimen. RESULTS: In this study, chest X-rays showed no abnormal changes after chemotherapy, but significant decreases in carbon monoxide diffusing capacity (DLCO) and percentage of the DLCO predicted value (DLCO%) (P<0.001). A significant increase in maximal ventilatory volume (MVV) (P=0.004) was observed, and most patients experienced dyspnea (P=0.031) and fatigue (P<0.001). However, there was no significant correlation between the changes in these PFTs parameters and the results of the EORTC QLQ-C30 (P>0.05). CONCLUSIONS: Neoadjuvant chemotherapy can reduce lung diffusion function and quality of life in females with breast cancer.
Authors: Pehr A Lind; Lawrence B Marks; Timothy A Jamieson; Dennis L Carter; James J Vredenburgh; Rodney J Folz; Leonard R Prosnitz Journal: Cancer Date: 2002-06-01 Impact factor: 6.860
Authors: Helena Earl; Elena Provenzano; Jean Abraham; Janet Dunn; Anne-Laure Vallier; Ioannis Gounaris; Louise Hiller Journal: BMC Med Date: 2015-09-22 Impact factor: 8.775
Authors: Theodore P Braun; Marek Szumowski; Peter R Levasseur; Aaron J Grossberg; XinXia Zhu; Anupriya Agarwal; Daniel L Marks Journal: PLoS One Date: 2014-09-25 Impact factor: 3.240
Authors: S Baulies; L Belin; P Mallon; C Senechal; J-Y Pierga; P Cottu; M-P Sablin; X Sastre; B Asselain; R Rouzier; F Reyal Journal: Br J Cancer Date: 2015-06-16 Impact factor: 7.640